Document Detail


Sm-p80-based DNA vaccine made in a human use approved vector VR1020 protects against challenge infection with Schistosoma mansoni in mouse.
MedLine Citation:
PMID:  20398225     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Although there is an effective drug (praziquantel) available for the treatment of schistosomiasis, yet the disease is still spreading unabated and is rampant in 76 countries. Control via praziquantel treatment has so far been insufficient in reducing the disease transmission. Therefore, a vaccine in addition to other strategies, for example, improving sanitation and introduction of new drugs are essential to successfully control and eventually eradicate schistosomiasis. To this effect, we have targeted a functionally important antigen, Sm-p80 as a vaccine candidate. In this study, full length cDNA of Sm-p80 was cloned in VR1020, a FDA approved vector for human use. The protective efficacy of this vaccine formulation was tested in a murine model. Sm-p80-VR1020 vaccine formulation was able to induce 47% reduction in worm burden. Serology on samples obtained from vaccinated animals revealed a strong antibody response which included IgG and all of its subtypes, IgM and IgA. Proliferating splenocytes in response to recombinant Sm-p80 produced a wide spectrum of cytokines representing Th1, Th2 and Th17 types, as ascertained via RT-PCR analysis. These findings further strengthen the importance of Sm-p80 molecule as a vaccine candidate for intestinal schistosomiasis.
Authors:
W Zhang; G Ahmad; W Torben; A A Siddiqui
Related Documents :
14547225 - The development of subunit and synthetic vaccines using recombinant dna technology.
19896675 - Duration of protection in animals: the point of view of regulators.
8561475 - Prospects for new interventions in the treatment and prevention of mycobacterial disease.
1806125 - Analyzing effects of vaccines.
23052615 - Sixty-four children with persistent itching nodules and contact allergy to aluminium af...
805535 - Use of a pseudomonas aeruginosa vaccine in pateints with acute leukemia and cystic fibr...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Parasite immunology     Volume:  32     ISSN:  1365-3024     ISO Abbreviation:  Parasite Immunol.     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-19     Completed Date:  2010-06-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7910948     Medline TA:  Parasite Immunol     Country:  England    
Other Details:
Languages:  eng     Pagination:  252-8     Citation Subset:  IM    
Affiliation:
Department of Microbiology and Immunology, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibodies, Helminth / blood
Antigens, Helminth / genetics,  immunology*
Cell Proliferation
Cytokines / secretion
Female
Genetic Vectors
Humans
Immunoglobulin A / blood
Immunoglobulin G / blood
Immunoglobulin M / blood
Leukocytes, Mononuclear / immunology
Mice
Mice, Inbred C57BL
Schistosoma mansoni / genetics,  immunology*
Schistosomiasis mansoni / immunology,  prevention & control*
Spleen / immunology
Vaccines, DNA / genetics,  immunology*
Grant Support
ID/Acronym/Agency:
R01AI071223/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/Antibodies, Helminth; 0/Antigens, Helminth; 0/Cytokines; 0/Immunoglobulin A; 0/Immunoglobulin G; 0/Immunoglobulin M; 0/Vaccines, DNA

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Enhanced protection by melatonin and meloxicam combination in experimental infection by Trypanosoma ...
Next Document:  Plasma lipoproteins in visceral leishmaniasis and their effect on Leishmania-infected macrophages.